Democrats to probe Trump-era MFN drug pricing deals

Incoming Democratic committee chairs are moving to investigate most-favored nation (MFN) drug pricing agreements, signaling a shift in oversight priorities. The probe targets deals that could affect pharmaceutical pricing and market access, though details remain unclear. This could lead to policy changes impacting drug pricing and industry dynamics.

AI disclosure: Model-written summary of the source, not a verified fact. Check the sources. How Mosaic works